Report scope. This 2026 Drug Asset Due Diligence Report evaluates Folinic Acid/Fluorouracil as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.
Executive recommendation: CONDITIONAL GO
Folinic Acid/Fluorouracil is a Small molecule drug associated with TYMS and a global highest development stage of Phase 2. The lead disclosed indication is Locally Advanced Pancreatic Adenocarcinoma. The current evidence supports a CONDITIONAL GO posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.
Decision memo
- Asset: Folinic Acid/Fluorouracil
- Target: TYMS
- Lead indication: Locally Advanced Pancreatic Adenocarcinoma
- Highest phase: Phase 2
- Matched trials: 20
- Matched result records: 18
- Matched asset deals: 0
Use PatSnap Life Sciences MCP servers to validate the Folinic Acid/Fluorouracil diligence evidence.
1. Asset identity and development status
The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Folinic Acid/Fluorouracil, the MCP profile identifies TYMS as the primary target context and Locally Advanced Pancreatic Adenocarcinoma as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.
Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.
Use PatSnap Life Sciences MCP servers to validate the Folinic Acid/Fluorouracil diligence evidence.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600130991 | Phase 2 | Pending | Not disclosed | Not disclosed |
| ACTRN12626000571370 | Phase 2 | Not yet recruiting | Not disclosed | Not disclosed |
| NCT06859762 | Phase 1 | Recruiting | Not disclosed | Not disclosed |
| ChiCTR2400088240 | Phase 2 | Not yet recruiting | Not disclosed | Not disclosed |
| ChiCTR2400087329 | Early Phase 1 | Recruiting | Not disclosed | Not disclosed |
| NCT06172036 | Phase 2 | Not yet recruiting | Not disclosed | Not disclosed |
| ACTRN12623000104651 | Phase 1 | Recruiting | Not disclosed | Not disclosed |
| KCT0004433 | Phase 2 | Active, not recruiting | Not disclosed | Not disclosed |
| ACTRN12619001533189 | Phase 1 | Completed | Not disclosed | Not disclosed |
| NCT04009876 | Phase 2 | Completed | Not disclosed | Not disclosed |
| NCT03880877 | Phase 2 | Unknown status | Not disclosed | Not disclosed |
| JPRN-jRCTs031180145 | Phase 3 | Complete | Not disclosed | Not disclosed |
| NCT03524508 | Phase 2 | Completed | Not disclosed | Not disclosed |
| NCT02697058 | Phase 2 | Completed | Not disclosed | Not disclosed |
| NCT02448810 | Phase 2 | Terminated | Not disclosed | Not disclosed |
| NCT01269216 | Phase 2 | Completed | Not disclosed | Not disclosed |
| JPRN-UMIN000002093 | Not Applicable | Complete: follow-up complete | Not disclosed | Not disclosed |
| NCT00201331 | Phase 2 | Unknown status | Not disclosed | Not disclosed |
| NCT00155558 | Phase 1 | Completed | Not disclosed | Not disclosed |
| ISRCTN18439984 | Phase 3 | Completed | Not disclosed | Not disclosed |
The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.
Use PatSnap Life Sciences MCP servers to validate the Folinic Acid/Fluorouracil diligence evidence.
3. Clinical readouts: what is known
CTP-02. A Phase 1 trial of Deflexifol™ in pediatric patients with relapsed or refractory brain tumors
Study: SNO2025. Phase: Phase 1. Enrollment: 9. Published: 2025-11-19.
DLT = Grade 3 oral mucositis and Grade 4 neutropenia Grade
369eP - Impact of ascites on treatment outcomes of Nal-IRI+5-FU/LV in patients with pancreatic cancer with peritoneal dissemination
Study: NAPOLI-1 (ESMO_GI2025). Phase: Phase 3. Enrollment: 55. Published: 2025-07-03.
Adverse Event: malaise = occurred in 33% (n = 6) of pts without MA and 100% (n = 7) of pts with ascites grade 3
A phase I dose-escalation study of an all-in-one 5-fluorouracil and leucovorin co-formulation administered after failure of standard treatment.
Study: ACTRN12619001533189 (ASCO_GI2024). Phase: Phase 1. Enrollment: 19. Published: 2024-01-18.
AE(Grade 1/2) = Grade 1/2 adverse events were fatigue, mucositis, and diarrhea.
O-9 5-FU/LV + cetuximab + vemurafenib as maintenance therapy for BRAF-mutant (BRAFmut) metastatic colorectal cancer: Efficacy, safety, and exploratory biomarker findings from Cohort 1 of the MODUL trial
Study: NCT02291289 (MODUL, ESMO_GI2021). Phase: Phase 2. Enrollment: 93. Published: 2021-07-03.
mPFS = 11.6 Month | mPFS = 10.0 Month
P-240 - Benefit of the addition of oxaliplatin to 5-FU/leucovorin or capecitabine in adjuvant therapy for stage II/III colorectal cancer in elderly patients: Experience in Ramon y Cajal University Hospital.
Study: ESMO_GI2018. Phase: Not Applicable. Enrollment: 551. Published: 2018-06-20.
DFS: HR = 0.14(95% CI, 0.02 - 0.66), P-Value = 0.013 | DFS: HR = 0.14(95% CI, 0.02 - 0.66), P-Value = 0.013
PD-018 - Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI±5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
Study: NCT02697058 (NAPOLI-1, ESMO_GI2017). Phase: Phase 3. Enrollment: Not disclosed. Published: 2017-06-28.
mOS = 6.7 Month | mOS = 4.2 Month
Deflexifol (a novel formulation of 5FU): Phase 1 dose escalation study of infusional and bolus schedules after failure of standard treatment.
Study: ASCO2017. Phase: Phase 1. Enrollment: 40. Published: 2017-05-30.
Adverse Event: toxicity = No > grade 1 toxicity was noted at 375-475 mg/m² bolus, or at 1200-2400 mg/m² infusion. The DLT in bolus schedule was grade 3 diarrhea and myelosuppression at 575 mg/m², with no DLT in the infusion schedule at the maximum dose 3600 mg/m². Other grade 3 toxicities were nausea, vomiting, and raised liver function tests.
5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer.
Study: ASCO2012. Phase: Not Applicable. Enrollment: 12. Published: 2012-05-20.
Pre-treatment CA 19-9 = 297 U/mL
Analysis of response rate (RR), liver resection (LR), and toxicity (T) in 129 advanced colorectal cancer (CRC) patients (pts) treated with chronomodulated infusion of ironotecan (I), 5-fluorouracil/leucovorin (F/L), and oxaliplatin (O) (CHRONO-IFLO) with or without cetuximab (Cmab).
Study: ASCO2011. Phase: Not Applicable. Enrollment: 129. Published: 2011-05-20.
LR = 29.6 % | LR = 48.0 %
A double-blind, randomized placebo-controlled, phase II study of maintenance enzastaurin (ENZ) with 5-FU/leucovorin (LV) plus bevacizumab (BV) following first-line therapy for metastatic colorectal cancer (mCRC).
Study: ASCO_GI2011. Phase: Phase 2. Enrollment: Not disclosed. Published: 2011-02-01.
mPFS = 5.8 Month | mPFS = 8.1 Month
5-FU/leucovorin (5FU/LV) combined with irinotecan (CPT-11) and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Study: ASCO2010. Phase: Not Applicable. Enrollment: Not disclosed. Published: 2010-05-20.
EFS(median) = 3 Month
Phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin (POF) in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Study: ASCO2010. Phase: Phase 2. Enrollment: 34. Published: 2010-05-20.
Anemia = 23.5 %
Phase I study of liposome irinotecan (PEP02) in combination with weekly infusion of 5-FU/LV in advanced solid tumors.
Study: ASCO2010. Phase: Phase 1. Enrollment: 16. Published: 2010-05-20.
AUC0→t = 354.77 ng×h/mL
Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial)
Study: ASCO2009. Phase: Not Applicable. Enrollment: 3278. Published: 2009-05-20.
MSI-H incidence = 22 % | MSI-H incidence = 12 %
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer.
Study: Pubmed | Ann Oncol. Phase: Phase 2. Enrollment: 80. Published: 2007-12-01.
PR = 52.5 % | PR = 55 %
Patterns of Recurrence in Adenocarcinoma of the Stomach After Postoperative Chemoradiotherapy
Study: INT-0116 (ASTRO2006). Phase: Phase 1/2. Enrollment: 111. Published: 2006-11-01.
Distant metastases = 28 % | Locoregional recurrences = 18 %
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (CPT-11 + oxaliplatin [IRINOX]) and two standard arms (LV5-FU2 + CPT-11 [FOLFIRI], LV5-FU2 + oxaliplatin [FOLFOX]) in first line metastatic colorectal cancer (MCRC) (FNCLCC Accord 08)
Study: FNCLCC Accord 08 (ASCO2006). Phase: Phase 2. Enrollment: 80. Published: 2006-06-20.
NCI G3-4 diarrhea = 33.3 % | NCI G3-4 diarrhea = 15 %
Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial
Study: ASCO2004. Phase: Phase 2. Enrollment: 34. Published: 2004-07-15.
RR = 72 %
For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.
Use PatSnap Life Sciences MCP servers to validate the Folinic Acid/Fluorouracil diligence evidence.
4. Market and competitive position
The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Folinic Acid/Fluorouracil against approved therapies and clinical competitors in Locally Advanced Pancreatic Adenocarcinoma, including likely standards of care at the expected launch date.
Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.
Use PatSnap Life Sciences MCP servers to validate the Folinic Acid/Fluorouracil diligence evidence.
5. Transaction precedent and economics
| Date | Transaction | Status | Type | Disclosed value |
|---|---|---|---|---|
| No exact asset-specific transaction was returned. Use target-level precedents only as comparables and do not present them as asset transactions. | ||||
Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.
6. IP and freedom-to-operate screen
Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.
The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.
Use PatSnap Life Sciences MCP servers to validate the Folinic Acid/Fluorouracil diligence evidence.
7. Principal risks and diligence gates
- Identity risk: resolve all aliases, formulations, combinations, and owners.
- Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
- Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
- IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
- CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
- Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
- Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.
8. Final go/no-go memorandum
CONDITIONAL GO
Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.
Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-15. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.
